Cancer biobank study aims to unlock secrets of immunotherapy resistance
NCT ID NCT06283238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future immunotherapies and better predict who will respond to treatment. The study was withdrawn before enrolling any participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can new drug cocktails reawaken the immune system against melanoma?
- Can switching cancer therapy early extend life in stomach cancer?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Can immunotherapy outperform chemo after stomach cancer surgery?